448 related articles for article (PubMed ID: 25549822)
1. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps.
Kerber R; Reindl S; Romanowski V; Gómez RM; Ogbaini-Emovon E; Günther S; ter Meulen J
J Clin Virol; 2015 Mar; 64():120-7. PubMed ID: 25549822
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and patient management of Lujo hemorrhagic fever.
Sewlall NH; Richards G; Duse A; Swanepoel R; Paweska J; Blumberg L; Dinh TH; Bausch D
PLoS Negl Trop Dis; 2014; 8(11):e3233. PubMed ID: 25393244
[TBL] [Abstract][Full Text] [Related]
3. [Arenavirus research and antiviral candidate].
Tani H; Shuzo U
Uirusu; 2018; 68(1):51-62. PubMed ID: 31105135
[TBL] [Abstract][Full Text] [Related]
4. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.
Torriani G; Trofimenko E; Mayor J; Fedeli C; Moreno H; Michel S; Heulot M; Chevalier N; Zimmer G; Shrestha N; Plattet P; Engler O; Rothenberger S; Widmann C; Kunz S
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626681
[TBL] [Abstract][Full Text] [Related]
5. The role of the vascular endothelium in arenavirus haemorrhagic fevers.
Kunz S
Thromb Haemost; 2009 Dec; 102(6):1024-9. PubMed ID: 19967131
[TBL] [Abstract][Full Text] [Related]
6. Zoonotic aspects of arenavirus infections.
Charrel RN; de Lamballerie X
Vet Microbiol; 2010 Jan; 140(3-4):213-20. PubMed ID: 19748747
[TBL] [Abstract][Full Text] [Related]
7. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
de la Torre JC
Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
[TBL] [Abstract][Full Text] [Related]
8. [Viral hemorrhagic fever--Ebola hemorrhagic fever, Marburg disease and Lassa fever].
Hotta H
Rinsho Byori; 1998 Jul; 46(7):651-5. PubMed ID: 9721531
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in the development of vaccines against hemorrhagic fevers caused by arenaviruses].
Mateo M; Baize S
Med Sci (Paris); 2023 Nov; 39(11):855-861. PubMed ID: 38018929
[TBL] [Abstract][Full Text] [Related]
10. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
Carnec X; Mateo M; Page A; Reynard S; Hortion J; Picard C; Yekwa E; Barrot L; Barron S; Vallve A; Raoul H; Carbonnelle C; Ferron F; Baize S
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593043
[TBL] [Abstract][Full Text] [Related]
11. Lassa virus.
Günther S; Lenz O
Crit Rev Clin Lab Sci; 2004; 41(4):339-90. PubMed ID: 15487592
[TBL] [Abstract][Full Text] [Related]
12. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
Martinez-Sobrido L; de la Torre JC
Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
[TBL] [Abstract][Full Text] [Related]
13. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses.
Lee AM; Rojek JM; Spiropoulou CF; Gundersen AT; Jin W; Shaginian A; York J; Nunberg JH; Boger DL; Oldstone MB; Kunz S
J Biol Chem; 2008 Jul; 283(27):18734-42. PubMed ID: 18474596
[TBL] [Abstract][Full Text] [Related]
14. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa.
Jeffs B
Trop Doct; 2006 Jan; 36(1):1-4. PubMed ID: 16483416
[TBL] [Abstract][Full Text] [Related]
15. Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques.
Rasmussen AL; Tchitchek N; Safronetz D; Carter VS; Williams CM; Haddock E; Korth MJ; Feldmann H; Katze MG
J Virol; 2015 Mar; 89(5):2543-52. PubMed ID: 25520505
[TBL] [Abstract][Full Text] [Related]
16. [Hemorrhagic (Marburg, Ebola, Lassa, and Bolivian) fevers: epidemiology, clinical pictures, and treatment].
Borisevich IV; Markin VA; Firsova IV; Evseev AA; Khamitov RA; Maksimov VA
Vopr Virusol; 2006; 51(5):8-16. PubMed ID: 17087059
[TBL] [Abstract][Full Text] [Related]
17. Novel drug discovery approaches for treating arenavirus infections.
Pasquato A; Kunz S
Expert Opin Drug Discov; 2016; 11(4):383-93. PubMed ID: 26882218
[TBL] [Abstract][Full Text] [Related]
18. A potent Lassa virus antiviral targets an arenavirus virulence determinant.
Madu IG; Files M; Gharaibeh DN; Moore AL; Jung KH; Gowen BB; Dai D; Jones KF; Tyavanagimatt SR; Burgeson JR; Korth MJ; Bedard KM; Iadonato SP; Amberg SM
PLoS Pathog; 2018 Dec; 14(12):e1007439. PubMed ID: 30576397
[TBL] [Abstract][Full Text] [Related]
19. [How to treat a patient with indications for an infectious viral hemorrhagic fever].
Visser LG; Schippers EF; Swaan CM; van den Broek PJ
Ned Tijdschr Geneeskd; 2002 Nov; 146(46):2183-8. PubMed ID: 12467160
[TBL] [Abstract][Full Text] [Related]
20. New opportunities for field research on the pathogenesis and treatment of Lassa fever.
Khan SH; Goba A; Chu M; Roth C; Healing T; Marx A; Fair J; Guttieri MC; Ferro P; Imes T; Monagin C; Garry RF; Bausch DG;
Antiviral Res; 2008 Apr; 78(1):103-15. PubMed ID: 18241935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
